| Project/Area Number |
15K14997
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Maeda Kazuya 東京大学, 大学院薬学系研究科(薬学部), 講師 (00345258)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肝星細胞 / トランスポーター / OATP2A1 / 肝線維化 / 活性化 / プロスタグランジン |
|---|
| Outline of Final Research Achievements |
This research intended to clarify whether membrane transporters expressed on the hepatic stellate cells (HSCs) can be a novel target for the suppression of the activation status of HSCs in liver injury, which leads to the amelioration of hepatic fibrosis. Based on the gene expression databases, we focused on transporter A, whose expression was similarly changed under multiple conditions. When inhibitors of the transport function of A were added to the LX-2 cells (immortalized HSCs), TGF-beta-dependent increased expression of COL1A1 and alpha-SMA was suppressed in an inhibitor concentration-dependent manner. Moreover, multiple siRNAs for gene A were introduced to LX-2 cells, the similar results were obtained. From these results, it was suggested that expression of transporter A in HSCs may contribute to the progression of the activation of HSCs.
|
